No Data
No Data
Sector Update: Health Care Stocks Flat to Higher Premarket Friday
BioCryst Says Orladeyo Prompted 'Significant' Drop Hereditary Angioedema Attacks in Study
BioCryst Pharma Presents New Real-World Evidence Showing ORLADEYO Delivers Sustained HAE Attack Reduction in Adolescents & Severe Cases
Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $17
BioCryst Gets Speedy FDA Review of Pediatric Use of Orladeyo
BioCryst Announces FDA Acceptance Of Its New Drug Application For Oral, Once Daily ORLADEYO In Hereditary Angioedema Patents Aged 2 To 11 Years